1 July 2016 in Journal of Veterinary Internal Medicine
Background: Lyme disease can affect people, dogs, and horses, but it remains poorly understood, especially in the horse. Determining the seroprevalence of Borrelia burgdorferi in horses in different geographic areas will enable better understanding of the epidemiology of the disease, thus improving diagnosis and treatment of affected animals. Hypothesis: To determine the seroprevalence of B. burgdorferi in horses in southwest Virginia. Animals: Horses presented for routine Coggins testing from January 2013 to January 2014 had additional blood drawn for Lyme Multiplex Assay testing. Methods: Of 492 samples collected, 250 samples were analyzed using the Lyme Multiplex Assay. Of the 83 horses that had positive test results to at least 1 outer surface protein (Osp), 63 were available for follow-up testing 5–17 months later (June 2014). Results: Thirty-three percent of horses had positive results for antibodies to at least 1 Osp. Horses with a positive outer surface protein F (OspF) result were older (14.5 ± 0.79) than horses with a negative OspF result (11.6 ± 0.53). Of the horses available for follow-up testing, 63% had the same result as that of the initial test. There was no difference in test result between initial and follow-up testing. Conclusions: Horses seropositive to B. burgdorferi are common in Virginia, and older horses are more likely to have a positive test result for OspF than younger horses. Follow-up testing indicated that the majority of horses that were positive on initial testing did not have a different test result 5–17 months later.
15 March 2011 in Journal of the American Veterinary Medical Association
Objective—To determine whether it is safe to vaccinate pregnant or postpartum mares with a commercial modified-live virus vaccine against equine viral arteritis (EVA). Design—Randomized controlled study. Animals—73 mares and their foals. Procedures—Mares were vaccinated during mid gestation, during late gestation, or 2 or 3 days after parturition with a commercial modified-live virus vaccine or were not vaccinated. Foaling outcomes were recorded, and serum, blood, milk, and nasopharyngeal samples were obtained. Results—All mares vaccinated during mid gestation foaled without any problems; 21 of 22 mares in this group had antibody titers against EAV at the time of foaling. Of the 19 mares vaccinated during late gestation, 3 aborted; antibody titers against EAV were detected in 13 of 15 mares from which serum was obtained at the time of foaling. All postparturient vaccinates were seronegative at foaling; all of them seroconverted after vaccination. No adverse effects were detected in any of their foals. Conclusions and Clinical Relevance—When faced with a substantial risk of natural exposure to EAV, it would appear to be safe to vaccinate healthy pregnant mares up to 3 months before foaling and during the immediate postpartum period. Vaccinating mares during the last 2 months of gestation was associated with a risk of abortion; this risk must be weighed against the much greater risk of widespread abortions in unprotected populations of pregnant mares naturally infected with EAV.
3 January 2024 in Equine Veterinary Education
Summary: Background: Equine granulocytic anaplasmosis (EGA) is a tick‐borne disease of clinical importance in Southwest Virginia. The diagnosis is based on clinical signs, detection of morulae on a blood smear, PCR and/or detection of antibodies 2–4 weeks post‐infection. A growing interest in stall‐side diagnostic tests has led to an increased use of the IDEXX SNAP 4DX Plus Test® for vector‐borne diseases including EGA. Objectives: The objectives of the study were to determine the seroprevalence of Anaplasma spp. in Southwest Virginia and examine the clinical and diagnostic features of symptomatic horses in the same region. Methods: Seroprevalence was evaluated in horses presented for Coggins testing in 2013 and 2019–2020. Clinical and diagnostic features were evaluated in horses presenting with compatible clinical signs from September 2019 to August 2020. Seroprevalence was determined using the IDEXX SNAP 4DX Plus Test®. Complete blood count, blood and buffy coat smears for morulae detection, PCR, immunofluorescence antibody testing (IFAT) and the IDEXX SNAP 4DX Plus Test® were performed on horses with clinical signs of EGA. Results: Seroprevalence of Anaplasma spp. was 8.5% in 2013 and 11.2% in 2019–2020 ( p = 0.43). 35% (6/17) of horses with clinical signs compatible with EGA had confirmed infection via PCR analysis. Three of these had morulae detected on blood smear and one had a positive IDEXX SNAP 4DX Plus Test®. Examination slides made from the buffy coat did not improve detection of morulae. The most common haematological abnormality was thrombocytopaenia. Conclusions: Seroprevalence of Anaplasma spp. is similar to other endemic areas in the United States. In active cases, diagnosis is best made via PCR. As anticipated, the IDEXX SNAP 4DX Plus Test® was not appropriate for the diagnosis of active infections.
1 December 2017 in Journal of Equine Veterinary Science
VBVirginia A. Buechner-Maxwell
Virginia A. Buechner-Maxwell
+1